<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051592</url>
  </required_header>
  <id_info>
    <org_study_id>2020/00339</org_study_id>
    <nct_id>NCT05051592</nct_id>
  </id_info>
  <brief_title>Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients</brief_title>
  <official_title>Role of Circulating Tumour DNA (ctDNA) Testing in Assessing for Alterations of Primary Anti-Epidermal Growth Factor Receptor (EGFR) Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore the clinical utility of circulating tumour DNA (ctDNA) in assessing&#xD;
      for alterations of anti-epidermal growth factor receptor (EGFR) primary resistance in RAS and&#xD;
      BRAF wild-type metastatic colorectal cancer (CRC) patients treated with anti-EGFR monoclonal&#xD;
      antibodies (cetuximab / panitumumab) in combination with fluorouracil (FU)-doublet&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single blood sample (20mL) will be collected after the patient has given informed consent.&#xD;
      The blood sample will be collected within 4 weeks prior to the patient starting chemotherapy.&#xD;
      Blood samples collected will be processed in accordance with the Guardant360 Clinical Blood&#xD;
      Collection Kit instructions (Guardant Health, Inc.).&#xD;
&#xD;
      Patient outcomes with respect to response rate, progression-free survival, overall survival,&#xD;
      toxicities and other co-morbid conditions will be ascertained by medical record review&#xD;
      conducted by the study personnel. Prospective clinical data that will be collected include:&#xD;
      patient demographics, tumor stage and pathological tumor characteristics at diagnosis,&#xD;
      laboratory data at diagnosis and serial pre-specified time points, imaging outcomes,&#xD;
      chemotherapy information, date of recurrence, and date and cause of death.&#xD;
&#xD;
      Although the data will be censored at the study end-points, the patient's medical record will&#xD;
      be reviewed indefinitely to follow the health outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of alterations of anti-epidermal growth factor receptor primary resistance using Circulating tumour DNA</measure>
    <time_frame>One timepoint, within 4 weeks prior to starting of anti-EGFR therapy</time_frame>
    <description>ctDNA analysis will be carried out using Guardant360 platform to identify subgroup of patients who have primary resistance to anti-EGFR therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Response rate to treatment received as per standard care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>The time from commencement of cancer treatment to disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>The length of time from start of treatment to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions experience by patient</measure>
    <time_frame>1 year 6 months</time_frame>
    <description>Toxicities in patients who have primary resistance to anti-EGFR therapy will be collected and analysed.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample collected from patient for this study, tumour or normal tissue removed or&#xD;
      biopsied as part of patient's routine care and body fluids (e.g. fluid lining the lungs or&#xD;
      effusion or fluid lining the abdomen or ascites) removed as part of patient's clinical care.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with newly diagnosed RAS/BRAF wild-type mCRC who are beginning standard-of-care&#xD;
        treatment with fluorouracil-based doublet chemotherapy in combination with anti-EGFR&#xD;
        monoclonal antibodies will be recruited into the study. These are patients who are cared&#xD;
        for at the National University Cancer Institute, Singapore (NCIS), and identified through&#xD;
        the colorectal surgery, medical oncology and multidisciplinary CRC tumour board at NCIS.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with newly diagnosed stage IV colon or rectal cancer who are RAS/BRAF&#xD;
             wild-type by routine tumor profiling and who are beginning standard-of-care treatment&#xD;
             with fluorouracil-based doublet chemotherapy in combination with anti-EGFR monoclonal&#xD;
             antibodies. Prior treatment with adjuvant therapy is allowed if completed more than 6&#xD;
             months prior to relapse of disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women will be excluded from the study.&#xD;
&#xD;
          -  Patient unable to give informed consent will be excluded from the study.&#xD;
&#xD;
          -  Patients who have previously received chemotherapy in the metastatic setting.&#xD;
&#xD;
          -  Patients who have previously received adjuvant chemotherapy less than 6 months prior&#xD;
             to relapse of metastatic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Ean Chee</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng Ean Chee</last_name>
    <phone>+65 6779 5555</phone>
    <email>cheng_ean_chee@nuhs.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng Ean Chee</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Ean Chee</last_name>
    </contact>
    <investigator>
      <last_name>Cheng Ean Chee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.</citation>
    <PMID>27380959</PMID>
  </reference>
  <reference>
    <citation>Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.</citation>
    <PMID>31539295</PMID>
  </reference>
  <reference>
    <citation>Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer. 2014 Apr;84(1):39-44. doi: 10.1016/j.lungcan.2014.01.013. Epub 2014 Jan 28.</citation>
    <PMID>24513263</PMID>
  </reference>
  <reference>
    <citation>Alix-Panabières C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016 May;6(5):479-91. doi: 10.1158/2159-8290.CD-15-1483. Epub 2016 Mar 11. Review.</citation>
    <PMID>26969689</PMID>
  </reference>
  <reference>
    <citation>Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5. Review.</citation>
    <PMID>29504847</PMID>
  </reference>
  <reference>
    <citation>Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014 Mar;11(3):129-44. doi: 10.1038/nrclinonc.2013.253. Epub 2014 Jan 21. Review.</citation>
    <PMID>24445517</PMID>
  </reference>
  <reference>
    <citation>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.</citation>
    <PMID>15175435</PMID>
  </reference>
  <reference>
    <citation>Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.</citation>
    <PMID>19339720</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ctDNA</keyword>
  <keyword>anti_EGFR</keyword>
  <keyword>RAS/RAF wild-type metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

